
Pharmacosmos took out the the big checkbook last week, when the family-owned company, which is based in Denmark, acquired the privately owned Boston-based business Abfero Pharmaceuticals.
The price tag may end up as much as USD 225m – when combining up-front and milestone payments, royalties, and more. The US-based company works within iron overload therapy, which is also the focus of Pharmacosmos, but the agreement's details are being kept under wraps.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app